Canyon Pharmaceuticals Announces Study Published in the Journal of Thrombosis and Haemostasis
00:01 EDT 20 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Orthopedic surgery patients with Stage 3B chronic kidney disease (CKD)
are at high risk for blood clots despite standard treatment with the
anticoagulant enoxaparin, according to a recently published study. Blood
clots and post-...
Other Sources for this Article
Media:
Canyon Pharmaceuticals
Dawn Bell, 973-387-1041
dawn.bell@canyonpharma.com
More From BioPortfolio on "Canyon Pharmaceuticals Announces Study Published in the Journal of Thrombosis and Haemostasis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
